In the third of this 3-part CEC Oncology BriefCase series, expert faculty and a patient advocate delve into interprofessional strategies for preventing and mitigating adverse events while collaboratively promoting QoL for patients being treated for HER2-negative MBC.
In the second of this 3-part CEC Oncology BriefCase series, expert faculty review emerging data on ADC therapy for HER2-negative MBC, describe therapy selection and treatment sequencing rationale, and hear from a patient advocate about patient concerns regarding this new therapy option.
In the first of this 3-part CEC Oncology BriefCase series, expert faculty introduce clinicians to ADC therapy for HER2-negative MBC and hear from a patient advocate about patient concerns regarding this new therapy option.
The third episode of this CEC BriefCase series continues to follow the same patient case and explores how to use shared decision making (SDM) to design strategies to monitor for and manage AEs in patients receiving ADCs.
The second episode of this CEC BriefCase series further explores the same patient case, demonstrates how to turn emerging therapies into practice changing treatment approaches, and considers when and to whom these therapies should be given and how gaps in guideline-concordant care lead to poorer treatment outcomes.
The first episode of this CEC BriefCase series introduces a patient case that demonstrates real-world challenges faced by oncologists and their teams, provides insights into the latest developments in this therapeutic space, and discusses how to consider swiftly developing data as a key component of personalized treatment plans.